Access the full text.
Sign up today, get DeepDyve free for 14 days.
E. Feldman, D. Alberts, Z. Arlin, T. Ahmed, A. Mittelman, P. Baskind, Y. Peng, M. Baier, P. Plezia (1993)
Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 11 10
Wheatley Wheatley (1996)
Meta‐analysis of randomized trials of idarubicin or mitoxantrone versus daunorubicin as induction therapy for acute myeloid leukemiaProceedings of American Society for Clinical Oncology, 15
M. Weiss, P. Maslak, E. Feldman, E. Berman, J. Bertino, T. Gee, Lori Megherian, K. Seiter, D. Scheinberg, D. Golde (1996)
Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 9
M. Goldberg, S. Imagawa, R. Strair, H. Bunn (1991)
Regulation of the erythropoietin gene in Hep 3B cells.Seminars in hematology, 28 3 Suppl 3
Mayer Mayer, Davis Davis, Schiffer Schiffer (1994)
Intensive postremission chemotherapy in adults with acute myeloid leukemiaNew England Journal of Medicine, 331
P. Schauer, Z. Arlin, R. Mertelsmann, C. Cirrincione, A. Friedman, T. Gee, M. Dowling, S. Kempin, D. Straus, B. Koziner (1983)
Treatment of acute lymphoblastic leukemia in adults: results of the L-10 and L-10M protocols.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1 8
Z. Arlin, Case Dc, J. Moore, P. Wiernik, E. Feldman, S. Saletan, P. Desai, L. Sia, K. Cartwright (1990)
Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group.Leukemia, 4 3
R. Willemze, W. Peters, L. Colly (1988)
Short‐term intensive treatment (V.A.A.P.) of adult acute lymphoblastic leukemia and lymphoblastic lymphomaEuropean Journal of Haematology, 41
LeMaistre LeMaistre, Herzig Herzig (1990)
Mitoxantrone: Potential for use in intensive therapySeminars in Oncology, 17
D. Hoelzer (1991)
High-dose chemotherapy in adult acute lymphoblastic leukemia.Seminars in hematology, 28 3 Suppl 4
KK Hussein, S. Dahlberg, David Head, CC Waddell, L. Dabich, J. Weick, F. Morrison, JH Saiki, E. Metz, SE Rivkin (1989)
Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy.Blood, 73 1
R. Ellison, R. Mick, J. Cuttner, C. Schiffer, R. Silver, E. Henderson, T. Woliver, I. Royston, F. Davey, A. Glicksman (1991)
The effects of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: a prospective randomized clinical trial by Cancer and Leukemia Group B.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 9 11
Arlin Arlin, Feldman Feldman, Finger Finger (1991)
Quality’ remissions: a new target of induction therapy in acute leukemia and the next step in developing curative treatmentSeminars in Hematology, 28
J. Klastersky, J. Sculier (1985)
Chemotherapy of non-small-cell lung cancer.Seminars in oncology, 12 4 Suppl 6
J. Moormeier, S. Williams, H. Golomb (1990)
The staging of non-Hodgkin's lymphomas.Seminars in oncology, 17 1
Alberts Alberts, Young Young, Mason Mason (1985)
In vitro evaluation of anticancer durgs against ovarian cancer at concentrations achievable by intraperitoneal administrationSeminars in Oncology, 12
Arlin Arlin, Case Case, Moore Moore (1990)
Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemiaLeukemia, 4
Dunn Dunn, Goa Goa (1996)
Mitoxantrone: A review of its pharmacological properties and use in acute nonlymphoblastic leukemiaDrugs ev Aging, 9
A. Keating, M. Gandhi, M. Crump, A. Smith, A. Belch, M. Baker (1996)
Treatment of acute myeloid leukemia (AML) at diagnosis in 99 unselected adults with high dose ARA-C (HIDAC) and mitoxantrone: Long-term follow-up.Blood, 88
Hussein K.K. (1989)
10.1182/blood.V73.1.57.57Blood, 73
Hiddemann Hiddemann, Aul Aul, Maschmeyer Maschmeyer (1991)
High‐dose versus intermediate dose cytarabine combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age‐adjusted randomized comparisonSeminars in Hematology, 28
Abildgaard Cf (1991)
Immunologic safety of recombinant factor VIII. The rFactor VIII Clinical Trial Group.Seminars in Hematology, 28
H. Kantarjian, R. Walters, M. Keating, T. Smith, S. O'Brien, E. Estey, Y. Huh, J. Spinolo, Dicke Ka, B. Barlogie (1990)
Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 8 6
R. Larson, R. Dodge, Burns Cp, Ej Lee, R. Stone, P. Schulman, D. Duggan, F. Davey, RE Sobol, S. Frankel (1995)
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.Blood, 85 8
Seiter Seiter, Feldman Feldman, Beer Beer (1995)
Phase II study of highdose mitoxantrone‐based induction therapy in patients with acute myeloid leukemiaBlood, 86
A. Mitus, K. Miller, D. Schenkein, H. Ryan, Shaun Parsons, C. Wheeler, J. Antin (1995)
Improved survival for patients with acute myelogenous leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 13 3
R. Mayer, Roger Davis, C. Schiffer, D. Berg, B. Powell, P. Schulman, G. Omura, J. Moore, O. Mcintyre, E. Frei (1994)
Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B.The New England journal of medicine, 331 14
Feldman Feldman, Seiter Seiter, Linker Linker (1995)
Intensive induction without consolidation in elderly patients with newly diagnosed acute myeloid leukemiaProceedings of American Society for Clinical Oncology, 14
C. Dunn, K. Goa (1996)
MitoxantroneDrugs & Aging, 9
Lee, Levitt, M. O'donnell, Stephen, Forman, Curt, Ries (1991)
Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report.Blood, 78 11
Based on promising preclinical data, a progressive series of evaluations of the use of high‐dose mitoxantrone‐based chemotherapy was initiated in acute leukaemia patients. A preliminary phase I study demonstrated that up to 80 mg/m2 of mitoxantrone in combination with cytarabine 3 g/m2 daily for 5 days could be given as induction therapy to leukaemic patients with acceptable toxicity. Pharmacokinetic data from these patients demonstrated that high concentrations of mitoxantrone were achievable in vivo to levels that were extremely cytotoxic in vitro. Subsequently, in a phase II study, 45 patients with untreated acute myelogenous leukaemia (AML) under the age of 60 received mitoxantrone 80 mg/m2 in combination with cytarabine 3 g/m2 daily for 5 days and etoposide 150 mg/m2 for 3 days. Following this induction, patients received five cycles of consolidation with cytarabine 3 g/m2 daily for 4 days with mitoxantrone 20 mg/m2 for 1 day on cycles 2 and 4, and etoposide 150 mg/m2 for 2 days with cytarabine on courses 1,3 and 5. The patients in this study achieved a complete remission (CR) rate of 80% and a 3‐year projected probability of survival of 40%. In a second AML study, 54 adults over the age of 60 with untreated AML were randomized to receive either high‐dose or standard‐dose mitoxantrone with cytarabine as a single induction regimen without consolidation. Patients receiving high‐dose mitoxantrone did not experience increased morbidity or mortality compared with those given lower doses. Comparison of CR rates, disease‐free and overall survival consistently favoured high‐dose mitoxantrone, although the results did not achieve statistical significance. In patients with acute lymphocytic leukaemia (ALL), high‐dose mitoxantrone with cytarabine was given as initial therapy in a phase II study involving 37 previously untreated adults. Results demonstrated that this dose‐intensive regimen could produce a high CR rate (84%) with acceptable toxicity and compared favourably with experiences with vincristine/prednisone‐based induction regimens. These studies demonstrate that high‐dose mitoxantrone can be safely and effectively administered to patients with acute leukaemia and suggest that the incorporation of high doses of mitoxantrone into treatment regimens may lead to enhanced antileukaemic efficacy compared with standard doses. Phase III evaluations are planned.
European Journal of Cancer Care – Wiley
Published: Jun 1, 1997
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.